Mast Therapeutics (MSTX) Slumps on EPIC Trial Outcome, Copart (CPRT) Delivers Strong Financial Performance


Shares of Mast Therapeutics, Inc. (NYSEMKT:MSTX) plummeted more than 75% to touch a new 52-week low in after-hours trading Tuesday as the company said that the late-stage EPIC trial evaluating its investigational drug vepoloxamer in patients with sickle cell disease did not achieve its primary efficacy endpoint in reducing the duration of vaso-occlusive crisis.

MSTX stock finished the regular session at $0.59 with a total volume of 16.05M shares traded, representing a large increase in activity versus its average volume (3m) of 4.30M

Mast Therapeutics, which develops therapies for serious or life-threatening diseases with unmet needs, has 211.82M Shares Outstanding. At close on Tuesday, the biopharmaceutical company had a Market Capitalization of $125.08M and MSTX stock one-year range was between $0.21 and $0.71 per share



Copart, Inc. (Nasdaq:CPRT) shares surged over 4% to nearly one-year high levels in the extended session Tuesday after the company delivered quarterly profit and revenue numbers above Wall Street analysts’ expectations

For its fourth quarter fiscal 206, Copart posted revenues of $332.7 million, a 17.8% increase year over year, and non-GAAP (excluding items) net income of $69 million, or $0.59 per diluted share, compared to non-GAAP net income of $59.02 million, or $0.45 per diluted share in the same quarter the priorr year, topping the Capital IQ Consensus Estimate of $0.55 earnings per share on revenues of $317.98 million for the period

CPRT stock closed at $51.41, up $0.67 (or +1.32%) and 833,893 of its shares changed hands during the day

Copart, which provides online auctions and vehicle remarketing services, has 109.38M Shares Outstanding, Market Capitalization (intraday) of $5.62B and CPRT stock 52-week range is from $32.26 to $53.70 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at